Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Cambrex completes $38 million expansion in North Carolina

by Rick Mullin
October 6, 2023 | A version of this story appeared in Volume 101, Issue 33

 

Pipework at a factory.
Credit: Cambrex
Cambrex has doubled production of small-molecule active pharmaceutial ingredients at its site in High Point, North Carolina.

Cambrex has completed a $38 million expansion at its manufacturing plant for small-molecule active pharmaceutical ingredients in High Point, North Carolina. The project doubles capacity at the site by adding analytical and chemical development laboratories, two clinical manufacturing suites, and three small-scale commercial manufacturing work centers with 2,000 L reactors. The enlarged operation is intended to coordinate with R&D and continuous-flow process development assets that Cambrex acquired last year with its purchase of Snapdragon Chemistry.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.